UNASSIGNED: @entity7995 associated with @entity15 and its animal model, experimental autoimmune @entity7995 (EAON), is characterized by @entity32 , T cell activation, @entity17 , and @entity528 , which might induce permanent @entity1018 . Elucidating the chronological relationship among the features is critical for treatment of demyelinating @entity7995 . EAON was induced in C57BL/6 @entity19 immunized with myelin oligodendrocyte glycoprotein subcutaneously, and visual function was assessed by flash-visual evoked potential (F-VEP) at days 7, 11, 14, 19, 23, 28 post-immunization. @entity2479 cell (RGC) apoptosis was measured by terminal-deoxynucleotidyl transferase-mediated nick-end labeling. @entity17 and @entity21 were verified with @entity10927 ( @entity10927 ) and b-amyloid precursor protein staining, respectively. Real-time polymerase chain reaction quantified @entity636 , @entity635 , @entity641 , @entity3744 , @entity777 , and @entity1618 mRNA expression in the optic nerve, as well as @entity3744 and @entity636 staining. Systemic changes of Th17 and Treg cells were tested by flow cytometry in spleen. F-VEP latency was prolonged at 11  days and peaked at 23  days commensurate with @entity17 . However, F-VEP amplitude was reduced at 11  days, preceding axon damage, and was exacerbated at 23  days when a peak in RGC apoptosis was detected. Th17 cells up-regulated as early as 7  days and peaked at 11  days, while Treg cells down-regulated inversely compared to Th17 cells change as verified by @entity636 and @entity3744 expression; spleen cell samples were slightly different, demonstrating marked changed at 14  days. Treg/Th17 cell imbalance in the optic nerve precedes and may initiate @entity528 of axons and RGCs. These changes are commensurate with the appearances of @entity227 reflected in F-VEP and hence may offer a novel therapeutic avenue for vision preservation.

Roles of Treg/Th17 Cell Imbalance and Neuronal Damage in the Visual Dysfunction Observed in Experimental Autoimmune XXXX Chronologically.

@entity1018 :: ('MESH:D054062', 'Disease') :: ['vision loss'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity17 :: ('MESH:D003711', 'Disease') :: ['Demyelination', 'demyelination'] @entity3744 :: ('20371(Tax:10090)', 'Gene') :: ['FoxP3'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual dysfunction'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['Retinal ganglion'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity635 :: ('16176(Tax:10090)', 'Gene') :: ['IL-1b'] @entity641 :: ('21803(Tax:10090)', 'Gene') :: ['TGF-b'] @entity1618 :: ('16153(Tax:10090)', 'Gene') :: ['IL-10'] @entity7995 :: ('MESH:D009902', 'Disease') :: ['optic neuritis', 'Optic neuritis'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['IL-6'] @entity10927 :: ('17196(Tax:10090)', 'Gene') :: ['myelin basic protein', 'MBP'] @entity21 :: ('MESH:D001480', 'Disease') :: ['axonal damage'] @entity636 :: ('16171(Tax:10090)', 'Gene') :: ['IL-17'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage']
@entity7995 :: (MESH:D009902,Disease) :: ['Optic Neuritis']
